Further Studies on the Hypercoagulable State of Patients with Cushing’s Syndrome

G M Patrassi; R Dal Bo Zanon; M Boscaro; S Martinelli; A Girolami

doi:10.1055/s-0038-1657887

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1985; 54(02): 518-520
DOI: 10.1055/s-0038-1657887

Original Article

Schattauer GmbH Stuttgart

Further Studies on the Hypercoagulable State of Patients with Cushing’s Syndrome

Authors

G M Patrassi

The Institute of Medical Semeiotics, University of Padua Medical School, Padua, Italy
R Dal Bo Zanon

The Institute of Medical Semeiotics, University of Padua Medical School, Padua, Italy
M Boscaro

The Institute of Medical Semeiotics, University of Padua Medical School, Padua, Italy
S Martinelli

The Institute of Medical Semeiotics, University of Padua Medical School, Padua, Italy
A Girolami

The Institute of Medical Semeiotics, University of Padua Medical School, Padua, Italy

Abstract

PDF Download

Summary

Factors XII, XI, IX and VIII, plasminogen and alpha₂-antiplasmin levels were found to be increased in a group of patients affected by Cushing’s syndrome. High activity of these coagulation factors could be due to their increased release and synthesis mediated by cortisol. A significant correlation between the main arterial pressure and either factor VIII antigen, ristocetin cofactor or factor XII activity was found. Moreover a similar correlation between factor XII activity and either factor VIII antigen or ristocetin cofactor was seen. In conclusion, the presence of a hypercoagulable state in Cushing’s syndrome seems confirmed. Synergic release of factor XII and factor VIII from endothelium could be due to high blood vessel tone secondary to hypercorticism. Finally, decreased fibrinolytic activity was suspected according to plasminogen and alpha₂-antiplasmin increase.

Keywords

Cushing’s syndrome - Hypercoagulable state - Hypertension

PDF (563 kb)

References

References
1 Isacson S. Effect of Prednisone on the coagulation and fibrinolytic systems. Scand J Haematol 1970; 7: 212-216
2 Cosgriff SW. Thromboembolic complications associated with A.C.T.H. and cortisone therapy. JAMA 1951; 147: 924-926
3 Chatterjea JB, Salomon L. Antagonist effect of A.C.T.H. and cortisone on the anticoagulant activity of ethyl biscoumacetate. Br Med J 1954; 2: 790-792
4 Ozsoylu S, Strauss HS, Diamond LK. Effects of corticosteroids on coagulation of the blood. Nature 1962; 195: 1214-1215
5 Pezzulich RA, Mannix H. Immediate complications of adrenal surgery. Ann Surg 1970; 172: 125-130
6 Blichert-Toft M, Bagerskov A, Lockwood K, Hasner E. Operative treatment, surgical approach, and related complications in 195 operations upon the adrenal glands. Surg Gynecol Obstet 1972; 135: 261-266
7 Dal Bo Zanon R, Fornasiero L, Boscaro M, Cappellato G, Fabris F, Girolami A. Increased factor VIII associated activities in Cushing’s syndrome: a probable hypercoagulable state. Thromb Haemostas 1982; 47: 116-117
8 Sjöberg HE, Blombäck M, Granberg PO. Thromboembolic complications, heparin treatment and increase in coagulation factors in Cushing’s syndrome. Acta Med Scand 1976; 199: 95-98
9 Chakrabarti R, Fearnley GR, Hocking ED. Effect of corticosteroid therapy on fibrinolysis in patients with inflammatory and noninflammatory conditions. Br Med J 1964; 1: 534-537
10 Gader AMA. The potentiating effect of cortisone (Prednisone) on the fibrinolytic and clotting factor VIII responses to intravenous infusion of adrenaline in man. Haemostasis 1982; 12: 353-356
11 Hoyer LW. The factor VIII complex: structure and function. Blood 1981; 58: 1-13
12 Landaburu RH, Castellanos DE. Further evidence of a humoral control of factor VIII plasma levels. Thrombos Diathes Haemorrh 1973; 30: 460-470
13 Girolami A, Sticchi A, Barbui T, Bareggi G. Factor VIII immunological assay. An evaluation of several methods using whole plasma. Blut 1974; 29: 309-316
14 Hardisty RM, Macpherson JC. A one-stage factor VIII (antihaemophilic globulin) assay and its use on venous and capillary plasma. Thrombos Diathes Haemorrh 1962; 7: 215-229
15 Macfarlane DE, Stibbe J, Kirby EP, Zucker MB, Grant RA, Macpherson J. A method for assaying von Willebrand factor (Ristocetin Cofactor). Thromb Haemostas 1975; 34: 306-308
16 Patrassi GM, Vettor R, Padovan D, Girolami A. Contact phase of coagulation in Diabetes mellitus. Europ J Clin Invest 1982; 12: 307-311
17 Soria C, Soria J, Samama MM. Dosage du plasminogène à l’aide d’un substrat chromogène tripeptidique. Pathol Biol 1976; 24: 725-729
18 Teger-Nilsson AC, Friberger P, Gyzander E. Antiplasmin determination by means of a chromogenic tripeptide substrate. In: Davidson F, Rowan RW, Samama MM, Desnoyers PC. (Eds.) New York: Raven Press; 1978: 305 313
19 Boscaro M, Karbowiak I, Mantero F. Radioimmunoassay of free urinary cortisol: clinical applications. J Nucl Med Allied Sci 1977; 21: 61-62
20 Girolami A, Cliffton EE. Hypercoagulable state induced in humans by the intravenous administration of purified ellagic acid. Thrombos Diathes Haemorrh 1967; 17: 165-175
21 Girolami A, Scarpa R, Solimbergo B. Tromboflebiti migranti ed ipercoagulabilità ematica da probabile attivazione del sistema fattore Hageman-PTA. Cardiol Prat 1968; 19: 17-23
22 Cliffton EE, Girolami A, Agostino D. The effect of ellagic acid on the thrombin-induced haemorrhagic syndrome in the rat. Blood 1966; 28: 253-257
23 Huges A, McVerry BA, Wilkinson L, Goldstone AH, Lewis D, Bloom A. Diabetes, a hypercoagulable state? Haemostatic variables in newly diagnosed type 2 diabetic patients. Acta Haematol 1983; 69: 254-259
24 Boneu B, Durand D, Connillon F, Charlet JP, Bierme R, Sue GM. Increased level in factor VIII complex in severe arterial hypertension. Haemostasis 1978; 7: 332-338
25 Simmons PS, Miles JM, Gerich JE, Haymond MW. Increased proteolysis. An effect of increases in plasma cortisol within the physiological range. J Clin Invest 1984; 73: 412-420
26 Patrassi GM, Fallo F, Martinelli S, Mantero F, Boeri G, Girolami A. The contact phase of blood coagulation and renin activation in essential hypertension before and after captopril. Eur Heart J 1984; 5: 561-567